DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Flovent Rotadisk (Fluticasone Propionate Inhalation) - Summary

 
 



SUMMARY

The active component of FLOVENT ROTADISK 50 mcg, FLOVENT ROTADISK 100 mcg, and FLOVENT ROTADISK 250 mcg is fluticasone propionate, a corticosteroid having the chemical name S-(fluoromethyl)6(alpha),9-difluoro-11(beta),17-dihydroxy- 16(alpha)-methyl-3-oxoandrosta-1,4-diene-17(beta)-carbothioate, 17-propionate.

FLOVENT ROTADISK is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

FLOVENT ROTADISK is NOT indicated for the relief of acute bronchospasm.


See all Flovent Rotadisk indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Flovent Rotadisk (Fluticasone Inhalation)

Reslizumab for Severe Asthma Gets Nod From EU Regulators
Source: Medscape Allergy & Clinical Immunology Headlines [2016.06.24]
The drug, already approved by the FDA, is an add-on maintenance drug for severe eosinophilic asthma that is not adequately controlled by high-dose inhaled corticosteroids.
International Approvals

The Asthma Prediction Rule to Decrease Hospitalizations
Source: Medscape Allergy & Clinical Immunology Headlines [2016.06.24]
Could this prediction rule help reduce unnecessary hospitalizations in children with acute asthma exacerbations?
Current Opinion in Allergy and Clinical Immunology

What is Asthma? Asthma Myths Debunked
Source: MedicineNet Asthma Complexities Specialty [2016.06.24]
Title: What is Asthma? Asthma Myths Debunked
Category: Slideshows
Created: 12/15/2008 12:00:00 AM
Last Editorial Review: 6/24/2016 12:00:00 AM

Severe Asthma Symptoms Persist After Decade of Treatment: ConsultantLive & Rheumatology Network
Source: MedPage Today Allergy & Immunology [2016.06.21]
(MedPage Today) -- Also, lupus linked to dementia risk?

Asthma: The Anatomy of an Asthma Attack
Source: MedicineNet Asthma Complexities Specialty [2016.06.10]
Title: Asthma: The Anatomy of an Asthma Attack
Category: Slideshows
Created: 3/16/2012 12:00:00 AM
Last Editorial Review: 6/10/2016 12:00:00 AM

more news >>

Published Studies Related to Flovent Rotadisk (Fluticasone Inhalation)

Fluticasone impact on airway dendritic cells in smokers: a randomized controlled trial. [2013]
DCs in smokers are unknown... CONCLUSIONS: Resistance to ICS monotherapy in smokers might in part be due to

Long-term monotherapy with suplatast tosilate in patients with mild atopic asthma: a pilot comparison with low-dose inhaled fluticasone. [2011.06]
BACKGROUND AND OBJECTIVE: Suplatast tosilate is a Th2 cytokine inhibitor that is effective for controlling persistent asthma. However, the long-term efficacy of suplatast is unknown. We compared the clinical efficacy of long-term monotherapy with suplatast tosilate with a low dose of inhaled steroids in patients with mild atopic asthma... CONCLUSIONS: Long-term treatment with suplatast significantly improved symptoms and inflammatory indices in patients with mild atopic asthma. Along with fluticasone, suplatast is considered a useful drug for the management of mild atopic asthma.

Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. [2011.05]
BACKGROUND: Fluticasone and formoterol are well established medications for the treatment of asthma. This study (Clinicaltrials.gov identifier: NCT00734318) compares the efficacy and safety of a combination of these drugs in a single inhaler (fluticasone/formoterol) versus the individual components (fluticasone + formoterol)... CONCLUSION: This study demonstrated that the fluticasone/formoterol combination is at least as effective as its components administered concurrently from separate inhalers. Fluticasone/formoterol (500/20 mug, b.i.d.) showed superior efficacy to its inhaled corticosteroid component alone and the efficacy of fluticasone/formoterol was dose-dependent for several clinically important parameters. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers. [2011.04]
PURPOSE: This study compares the in vivo relative lung bioavailability of Hydrofluoroalkane (HFA) Seretide delivered via unprimed and unwashed Aerochamber Plus (AP) or Volumatic (VM) spacers, a integrated breath-actuated vortex Synchro-Breathe (SB) device and an Evohaler pMDI (EH) device using adrenal suppression and early fall in serum potassium (K) as surrogates for respirable dose... CONCLUSIONS: The breath-actuated SB device was comparable to 'out of the box' small and large volume spacers and produced similar improvements in relative systemic lung bioavailability for fluticasone and salmeterol.

Difference between patient-reported side effects of ciclesonide versus fluticasone propionate. [2010.12]
RATIONALE: Patient-reported outcomes provide new insights into the dynamics of asthma management. Further to asthma control and quality of life, self-reported side effects of treatment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ). OBJECTIVES: To compare patient-reported side effects between the inhaled corticosteroids ciclesonide and fluticasone propionate... CONCLUSION: Patient-perceived side effects differ depending on the type of inhaled corticosteroids used. Patients with moderate-to-severe asthma report less intense side effects assessed with ICQ with ciclesonide than with fluticasone propionate. CLINICAL TRIAL REGISTRATION: The reported trials were completed before July 1 2005 and, therefore, are not registered. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

more studies >>

Clinical Trials Related to Flovent Rotadisk (Fluticasone Inhalation)

Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth [Recruiting]
Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller. Inhaled corticosteroids are the standard treatment for mild peristent asthma. The purpose of this study is to measure children rate of growth while on different inhaled corticosteroids.

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg Twice Daily In Symptomatic Patients With Asthma [Completed]
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma [Completed]
This purpose of this study is to show the superiority and long term safety and efficacy of adding a long acting beta agonist (salmeterol) to constant dose of an inhaled corticosteroid (fluticasone propionate) in symptomatic subjects with asthma. The 12-month assessment of asthma control will provide key information on the efficacy and safety of the combination therapy. The safety measure will be an assessment of adverse events

FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects [Completed]
The purpose of this study is to address an Food Drug and Administration (FDA) request to provide safety data in pre-asthmatic patients, ages 6 months to <12 months, following administration of fluticasone propionate HFA.

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENTŪ DISKUSŪ and ADVAIRŪ DISKUSŪ in Patients With Persistent Asthma 12 Years of Age and Older [Active, not recruiting]
Each patient will participate in the study for approximately 7 weeks. Participation will include a screening period of up to 21 days and 4 treatment periods; each consisting of a 3-day/2-night inpatient period.

more trials >>


Page last updated: 2016-06-24

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015